An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2016
At a glance
- Drugs Dovitinib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 15 Apr 2016 Results published in the Hepatology
- 13 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2014 Planned End Date changed from 1 Jul 2013 to 1 Apr 2014, as per ClinicalTrials.gov record.